Business
The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute
IRVING, Texas, Dec. 19, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"IRVING, Texas, Dec. 19, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that Providence Swedish Cancer Institute and the institute's focused translational research extension, the Paul G. Allen Research Center, have joined the Caris Precision Oncology Alliance™ (Caris POA).\n \n \n \n \n \n \n \nThe Providence Swedish Cancer Institute, located in Seattle, Washington, focuses on innovative cancer diagnosis and treatment utilizing a multidisciplinary team of providers focused exclusively on cancer care, from diagnosis to treatment to survivorship. The institute's specialists have helped develop screening tests, technologies and therapies that are helping cancer patients around the world.\"We are proud to welcome the Providence Swedish Cancer Institute and the Paul G. Allen Research Center to the Caris Precision Oncology Alliance. They strive to provide patients with earlier access to promising therapies,\" said James Hamrick, MD, MPH, Chairman of the Caris POA. \"Their scale, expertise and commitment to research-driven care make them an ideal institution in our shared commitment to accelerate precision oncology and deliver better options and outcomes for patients.\"The Caris POA is a global network of leading cancer centers and research groups collaborating to advance precision oncology and biomarker-driven research. Members work together to set and refine molecular testing standards, leverage Caris' AI and machine-learning bioinformatics, and access a large multimodal database to accelerate innovative studies and improve clinical outcomes for patients.\"Caris and the Center Institute share a deep commitment to collaborative, patient-centered innovation, which is why I'm so pleased we're joining the Caris Precision Oncology Alliance,\" said Ashwani 'Ash' Rajput, MD, Executive Medical Director of the Providence Swedish Cancer Institute. \"Together we can accelerate access to leading-edge therapies by leveraging shared resources to turn promising ideas into scalable solutions that improve outcomes for patients now and into the future.\"Following the addition of the Providence Swedish Cancer Institute, the Caris POA now consists of 99 cancer centers, academic institutions, research consortia and healthcare systems, i...